Milrinone is a phosphodiesterase 3 inhibitor with both positive inotropic and vasodilator properties. Administered as a continuous infusion, milrinone is indicated for the short-term treatment of patients with acute decompensated heart failure” Curley et al (2017).
Abstract:
Milrinone is a phosphodiesterase 3 inhibitor with both positive inotropic and vasodilator properties. Administered as a continuous infusion, milrinone is indicated for the short-term treatment of patients with acute decompensated heart failure. Despite limited data supporting long-term milrinone therapy in adults with congestive heart failure, children managed as outpatients may benefit from continuous milrinone as a treatment for cardiac dysfunction, as a destination therapy for cardiac transplant, or as palliative therapy for cardiomyopathy. The aim of this article is to review the medical literature and describe a home infusion company’s experience with pediatric outpatient milrinone therapy.
[ctt link=”_6Fhc” template=”1″]ReTweet if useful… Home infusion company’s experience with pediatric outpatient milrinone therapy https://ctt.ec/_6Fhc+ @ivteam #ivteam[/ctt]
[button link=”http://journals.lww.com/journalofinfusionnursing/Fulltext/2017/03000/Continuous_Intravenous_Milrinone_Therapy_in.3.aspx” color=”default”]Full Text[/button]
[spacer height=”20px”]
Reference:
Curley, M., Liebers, J. and Maynard, R. (2017) Continuous Intravenous Milrinone Therapy in Pediatric Outpatients. Journal of Infusion Nursing. 40(2), p.92–96.
doi: 10.1097/NAN.0000000000000214
Thank you to our partners for supporting IVTEAM
[slideshow_deploy id=’23788’]